Predictors of severe esophagitis include use of concurrent chemotherapy, but not the length of irradiated esophagus: A multivariate analysis of patients with lung cancer treated with nonoperative therapy

International Journal of Radiation Oncology Biology Physics

Volumn 48, Issue 3, 2000, Pages 689-696

  Werner Wasik, Maria ^a,b   Pequignot, Edward ^a   Leeper, Dennis ^a   Hauck, Walter ^a   Curran Jr , Walter ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Chemotherapy; Esophagitis; Lung cancer; Multivariate analysis; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DOSIMETRY; ESOPHAGITIS; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; COMBINED MODALITY THERAPY; ESOPHAGITIS; ESOPHAGUS; FEMALE; FORECASTING; HUMAN; LUNG NEOPLASMS; MALE; MIDDLE AGE; PROSPECTIVE STUDIES; RADIOTHERAPY DOSAGE; SEVERITY OF ILLNESS INDEX; SEX FACTORS;

EID: 0034307213     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(00)00699-4     Document Type: Article

References (19)

1. Byhardt R.W., Scott C., Sause W.T., et al. Response, toxicity, failure patterns, and survival in five RTOG trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys. 42:1998;469-478.
2. Choy H., Akerely W., Safran H., et al. Multiinstitutional Phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small cell lung cancer. J Clin Oncol. 16:1998;3316-3322.
3. Werner-Wasik M., Scott C., Graham M.L., et al. Interfraction interval does not affect survival of patients with non-small cell lung cancer treated with chemotherapy and/or hyperfractionated radiotherapy A multivariate analysis of 1076 RTOG patients . Int J Radiat Oncol Biol Phys. 44:1999;327-331.
4. Saunders M.I., Dische S., Barrett A., et al. Randomized multicentre trials of CHART vsconventional radiotherapy in head and neck and non-small cell lung cancer An interim report . Br J Cancer. 73:1996;1455-1462.
5. Langer C.J. Concurrent chemoradiation using pacltaxel and carboplatin in locally advanced non-small cell lung cancer. Semin Radiat Oncol. 9:1999;108-116.
6. Choy H., LaPorte K., Knill-Selby E., et al. Esophagitis in combined modality therapy for locally advanced non-small cell lung cancer. Semin Radiat Oncol. 9:1999;90-96.
7. Ball D., Bishop J., Smith J., et al. A Phase III study of accelerated radiotherapy with and without carboplatin in nonsmall cell lung cancer An interim toxicity analysis of the first 100 patients . Int J Radiat Oncol Biol Phys. 31:1995;267-272.
8. Werner-Wasik M., Rudoler S., Preston P.E., et al. Immediate side effects (ISE) of Stereotactic Radiotherapy and radiosurgery. Int J Radiat Oncol Biol Phys. 43:1999;299-304.
9. Rowland M, Tozer T. Assessment of area under the curve. In: Rowland M, Tozer T, editors. Clinical pharmacokinetics. Concepts and applications. 3rd ed. Baltimore: Williams and Wilkins; 1995, p. 469-472.
10. Cox J.D., Pajak T.F., Asbell S., et al. Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung Analysis of 1244 cases from 3 RTOG trials . Int J Radiat Oncol Biol Phys. 27:1993;493-498.
11. Koukourakis M., Hlouverakis G., Kosma L., et al. The impact of overall treatment time on the results of radiotherapy for nonsmall cell lung carcinoma. Int J Radiat Oncol Biol Phys. 34:1996;315-322.
12. Turrisi AT, Glover DJ, BA Mason. A preliminary report: concurrent twice daily radiotherapy plus platinum-etoposide chemotherapy for limited small cell lung cancer. Int J Radiat Oncol Biol Phys 1998;15:183-187.
13. Michalowski A., Hornsey S. Assays of damage to the alimentary canal. Br J Cancer. 53:(Suppl. VII):1986;1-6.
14. Umsawasdi T., Valdivieso M., Barkley H.T., et al. Esophageal complications from combined chemoradiotherapy (cyclophosphamide + adriamycin + cisplatin + XRT) in the treatment of non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 11:1985;511-519.
15. Boal D.K., Newburger P.E., Teele R.L. Esophagitis induced by combined radiation and adriamycin. AJR. 132:1979;567-570.
16. Vokes E.E., Leopold K.A., Herndon J.E., et al. A randomized phase II study of gemcitabine or paclitaxel or vinorelbine with cisplatin as induction chemotherapy and concomitant chemoradiotherapy for unresectable stage III non-small cell lung cancer (NSCLC). Proceed Am Soc Clin Oncol. 18:1999;459a.
17. Bailey A.J., Parmar M.K.B., Stephens R.J. Patient-reported short-term and long-term physical and psychologic symptoms Results of the Continuous Hyperfractionated Accelerated Radiotherapy (CHART) randomized trial in non-small cell lung cancer . J Clin Oncol. 16:1998;3082-3093.
18. Dubray B., Livartowski A., Beuzeboc P., et al. Combined chemoradiation for locally advanced nonsmall cell lung cancer. J Infus Chemotherapy. 5:1995;195-196.
19. Maguire P.D., Sibley G.S., Zhou S.M., et al. Clinical and dosimetric predictors of radiation-induced esophageal toxicity. Int J Radiat Oncol Biol Phys. 45:1999;97-103.